The purpose of this FOA is to stimulate research in understanding the interplay between different cell death pathways in naïve and drug resistant cancers. This emerging area promotes the concept that cell death pathways are interconnected and cells resistant to one type of cell death may become sensitive to other types of cell death, leading to novel therapeutic opportunities. The long-term goal is to understand how cancer cell death programs intersect at the molecular level so that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving cancer cells toward effective cell death. Understanding the basics of cell death crosstalk in cancer is important in addressing current and future challenges in targeting cancer cell death as a therapeutic approach. Furthermore, revealing differences in cell death profiles across cancer types and within individual cancer patients will help to develop precise tools to treat drug-resistant cancers.
This FOA is suitable for projects where proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available.
This FOA runs in parallel with an FOA of similar scientific scope, PA-17-449 which utilizes the Exploratory/Developmental Grant (R21) mechanism.